Sectors
Data room providers for biotech and life sciences
Licensing deals and trial data mean life sciences rooms need scientific document handling and IP protection that generic M&A platforms treat as an afterthought.
Vault Index desk / 9 August 2026 / 8 min read
The short answer
Datasite Diligence is widely used for biotech licensing and M&A given its scale and familiarity among pharma corporate development teams. iDeals is a strong alternative for smaller biotech deals wanting robust IP protection without enterprise pricing. Drooms has a following among European life sciences companies given its data residency options within the EU. Ansarada suits companies running a structured partnering or licensing process with multiple pharma counterparties bidding for the same asset. EthosData has built a specific reputation in life sciences and pharma licensing deals over many years, which makes it worth shortlisting even though it is less known outside the sector. SmartRoom is another option seen in pharma and biotech transactions, particularly where the buyer already uses it for other categories of deal. 99 Data Rooms has limited presence in this sector so far and is realistically only worth trialling for smaller licensing or asset deals rather than full trial data disclosure.
What a life sciences deal actually needs that other sectors do not
Biotech and pharma deals routinely involve disclosing trial data, patent portfolios and manufacturing process documents that are both commercially priceless and technically dense. The room needs granular, document-level watermarking and view-only rendering that prevents a competitor bidder team from downloading and reverse-engineering a formulation or process document, even under a signed NDA.
Search and indexing also matter more here than in most sectors, since a diligence team may need to locate a specific trial endpoint or adverse event record across thousands of pages of clinical data. A room with weak full-text search meaningfully slows down a life sciences diligence process compared with one built for large document volumes.
The document index for a licensing or M&A process
A typical life sciences room includes: patent portfolios and freedom-to-operate opinions, clinical trial protocols and data by phase, regulatory correspondence with bodies such as the FDA, EMA or MHRA, manufacturing and quality agreements, key opinion leader and investigator agreements, and licensing or collaboration agreements with other pharma partners.
Given the regulatory correspondence often includes safety and adverse event data, this section should sit behind an additional, more restricted permission tier than the rest of the room, visible only to the buyer's medical and regulatory advisers rather than the full deal team.
Pricing and procurement
Pricing across the enterprise vendors used in this sector is almost universally on request, reflecting the scale and duration of typical licensing negotiations, which can run for many months (Datasite, 2026; EthosData, 2026). Ask specifically whether the quote covers the full negotiation period, since a licensing process that drags on longer than expected can trigger unplanned renewal fees.
Smaller biotech companies running an early partnering process on a limited budget should get quotes from at least one enterprise vendor and one mid-market vendor such as iDeals before committing, since the price gap between the two tiers is often larger than the feature gap for a smaller deal.
Compliance and evidence
Confirm the vendor's data residency options align with where trial data was originally collected, since patient-level data may carry its own jurisdiction-specific handling requirements separate from general corporate confidentiality obligations. ISO 27001 certification is standard among the vendors named here, but ask for evidence the certificate scope covers the specific hosting region being used for the deal.
Given the value of the IP at stake, ask for a demonstration of the watermarking and screenshot-deterrence features rather than accepting a description on a features page, since implementation quality varies more than vendors' marketing suggests.
Where to go from here
See /rankings for the full comparison and /methodology for how security and document handling are weighted for a sector like this one.
Sources and further reading
- EthosData, life sciences deal experience
- Drooms, EU data residency
- MHRA, clinical trial data guidance
- Datasite, life sciences sector page
Vendor figures rechecked 1 September 2026
Vault Index